PCM 075

Drug Profile

PCM 075

Alternative Names: NMS-1286937; NMS-937; PCM-075

Latest Information Update: 18 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Nerviano Medical Sciences
  • Developer Nerviano Medical Sciences; TrovaGene
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Polo-like kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Acute myeloid leukaemia

Most Recent Events

  • 16 Aug 2017 Pharmacodynamics data from a preclinical study in acute myeloid leukaemia released by Trovagene
  • 16 Aug 2017 Trovagene plans a clinical trial for Acute myeloid leukaemia in
  • 28 Jul 2017 The US FDA approves IND application for a phase Ib/II trial for Acute Myeloid Leukemia (Combination therapy)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top